This announcement is a separate document:
大信会计师事务所（特殊普通合伙） 关于上海证券交易所《关于嘉必优生物技术（武汉）股份有限公司2022年业绩快报更正暨资产减值风险、补充确认关联交易等有关事项的问询函》回复的核查意见
Verification opinion of Daxin Certified Public Accountants (Special General Partnership) on the Shanghai Stock Exchange's response to the Shanghai Stock Exchange's “Inquiry Letter on Matters Related to the Correction of Jiabiyou Biotechnology (Wuhan) Co.,
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.